KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:待检查 入排置信度 0.96

Clinical efficacy of apalutamide in Asian patients with metastatic castration-sensitive prostate cancer: Bayesian reanalysis of the TITAN trial.

Wei Chen, Soichiro Yoshida, Akihiro Hirakawa, Hiroyuki Sato, Shugo Yajima, Masaki Kobayashi, Motohiro Fujiwara, Hiroshi Fukushima, Yuki Arita, Yuma Waseda, Hajime Tanaka, Hitoshi Masuda, Yasuhisa Fujii

Jpn J Clin Oncol 56(4) 455-460

PMID41450247
PMCID-
DOI10.1093/jjco/hyaf206
发表日期2025-12-26
入排依据:属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
入排复审未纳入:属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
摘要

摘要

BACKGROUND: The phase 3 TITAN trial revealed that apalutamide plus androgen deprivation therapy (ADT) has significantly improved outcomes in patients with metastatic castration-sensitive prostate cancer (mCSPC). However, the generalizability of these results to Asian and Japanese populations remains unclear. Bayesian methods provide a probabilistic framework offering more clinically meaningful estimates of benefit in such subpopulations. METHODS: We conducted a Bayesian post hoc analysis using reconstructed individual patient data from the published Asian (n = 221) and Japanese (n = 51) TITAN trial subpopulations. Bayesian Cox proportional hazards models were fitted under four prespecified priors representing different skepticism levels. Posterior median hazard ratios (HRs), 95% credible intervals (CrIs), and probabilities of any benefit (Pr[HR < 1.0]) or substantial benefit (Pr[HR < 0.8]) were calculated. RESULTS: The posterior median HR under the neutral prior for overall survival in the Asian cohort was 0.71 (95% CrI 0.44-1.14), with Pr[HR < 1.0] = 92% and Pr[HR < 0.8] = 69%. Probabilities exceeded 95% under more informative priors. The Japanese cohort demonstrated more pronounced effects (neutral prior HR: 0.55, 95% CrI: 0.22-1.35) with ≥90% probability of benefit across all priors. Posterior median HRs for TTmCRPC were 0.32-0.35 across priors, with ~100% probability of treatment benefit in both cohorts. CONCLUSION: This analysis provides strengthened evidence that apalutamide plus ADT offers meaningful clinical benefit for Asian patients with mCSPC. Moreover, our findings support more informed and individualized clinical decision-making, helping clinicians communicate expected outcomes more clearly during shared decision-making.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。